This study shows a difference in both vertex hair and serum DHT levels when compared to non-balding men. Crucially however there is no difference in occipital hair DHT levels between male pattern baldness sufferers and controls. So even though the there was a serum difference it didnt seem to effect local hair follicle levels. This tends to indicate that f there is more DHT in the blood it is merely indicative of greater local activity. This is what the researchers confirm when they say that the increased DHT/T ratio in blood is merely indicative of greater 5AR-2 activity.
J Dermatol Sci. 2004 Feb;34(1):11-6.Click here to read Links
Comparative studies on level of androgens in hair and plasma with premature male-pattern baldness.
Bang HJ, Yang YJ, Lho DS, Lee WY, Sim WY, Chung BC.
Bioanalysis and Biotransformation Research Center, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul 130-650, South Korea.
BACKGROUND: It is well known that male-pattern baldness (male pattern baldness) is not started from occipital, but frontal or scalp of head. We can assume that distribution of androgenic steroids is different for each region of the head. OBJECTIVE: We hypothesize that the levels of androgenic steroids are different not only between vertex hair with male pattern baldness and controls but also between occipital hair with male pattern baldness and controls. Moreover, we want to search for the biochemical indicator in plasma and hair sample (baldness: 22, non-baldness: 13) obtained from dermatology of medical center. After then, we desire to present fundamental data regarding diagnosis, medical cure, and prevention for premature male pattern baldness. METHODS: After hair and plasma were hydrolyzed, and then extracted with organic solvent. To assess androgenic steroids levels, we used gas chromatography-mass spectrometry (GC-MS) system in selected ion monitoring mode. RESULTS:
The level of dihydrotestosterone (DHT) and the ratio of testosterone to epitestosterone (T/E ratio) in vertex hair from premature baldness subjects were higher than in the sample of non-baldness subjects (P<0.001, 0.001), whereas the levels of androgens in occipital hair from the same baldness group were not different. In addition, we discovered the levels of DHT, testosterone, and DHT/T ratio in plasma from premature male pattern baldness were higher than in those of control subjects (P<0.001, 0.001, 0.005). CONCLUSION: We verified that the distribution of androgenic steroids is unlike in various regions of individual subjects. Moreover, the increased DHT/T ratio in balding plasma indirectly confirms the high activity of 5alpha-reductase type II.
Same group now looking at men before and after finasteride. Interesting to note that neither of these papers are looking at scalp levels - ie other studies on dutasteride/finasteride take a piece of scalp and basically blend it into a bloody liquid and then measure DHT. These guys are looking at androgen concentrations in the hair itself. I dont know if this is a better or worse indicator than scalp levels. Nevertheless it confirms with what others have found about more 5-AR expression and DHT in balding areas.
Br J Dermatol. 2006 Apr;154(4):730-4.Click here to read Links
Evaluation of androgens in the scalp hair and plasma of patients with male-pattern baldness before and after finasteride administration.
Ryu HK, Kim KM, Yoo EA, Sim WY, Chung BC.
Bioanalysis and Biotransformation Research Centre, Korea Institute of Science and Technology, PO Box 131, Cheongryang, Seoul, 130-605, Korea.
BACKGROUND: Finasteride, a competitive inhibitor of the enzyme 5alpha-reductase II, is widely used as a medical treatment for patients with male-pattern baldness (male pattern baldness), which is affected by the distribution of androgenic steroids. It is also notable that the androgenic effect in male pattern baldness is different for each region of the head. OBJECTIVES: To study the effect of the drug finasteride, we quantified androgenic steroids in the vertex and occipital scalp hair and in the plasma of patients with male pattern baldness. METHODS: The patients with male pattern baldness, aged 23-52 years, were treated with finasteride 1 mg daily for 5 months. The hair and plasma samples were hydrolysed, extracted with n-pentane, and derivatized with MSTFA:NH4I
TE (1000:4:5, v/w/w). We analysed the concentrations of dihydrotestosterone (DHT) and testosterone (T) in the hair and plasma using gas chromatography-mass spectrometry (GC-MS). RESULTS:
In the hair, the ratio of DHT/T was decreased in the vertex scalp hair after the individual received finasteride (P < 0.005). However, we found no significant difference in the ratio of DHT/T in the occipital scalp hair before and after individuals received finasteride. Like the results in the vertex scalp hair, the ratio of DHT/T in the plasma was remarkably decreased after finasteride administration (P < 0.001). CONCLUSIONS: This study supports the effect of finasteride in patients with male pattern baldness by examining the decreased level of DHT/T in scalp hair and in plasma. Thus, in view of the androgenic effect in the different hair regions, the vertex scalp hair plays a more important role for patients with male pattern baldness treated with finasteride than does the occipital hair.